TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05158348
Drug: Local infiltration of lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: group C will receive intra-operative local infiltration of lidocaine
Study: NCT04802746
Drug: Alprazolam
Normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study participants will receive Staccato alprazolam Dose 1 and Staccato alprazolam Dose 2 at pre-specified time points in Part A. Study participants will receive single dose of Staccato alprazolam at pre-specified time points in Part B.
Study: NCT05771428
Drug: ABBV-552
Normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Capsule
Study: NCT06004661
Drug: 68Ga-PSMA-11
Normalized name: 68Ga-Psma-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous dose of approximately 150 MBq
Study: NCT04914897
Drug: THOR-707
Normalized name: IL-2 variant THOR-707
DrugBank: Pegenzileukin (DB17495)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion: solution for infusion
Study: NCT04914897
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous infusion: solution for infusion
Study: NCT05091346
Drug: E7386
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: E7386 tablet.
Study: NCT05091346
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab IV infusion.
Study: NCT05091346
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenvatinib capsule.
Study: NCT04714372
Drug: Daratumumab/rHuPH20
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daratumumab 1800 mg co-formulated with 30,000 units of hyaluronidase (rHuPH20) given subcutaneously into subcutaneous tissue of the abdomen approximately 3 inches \[7.5 cm\] to the right or left of the navel over approximately 3-5 minutes on Day -12 and Day -5 prior to the 1st FT538 infusion, and on Day +3, Day+10, and Day+17 approximately 48 hours after each FT538 infusion.
Study: NCT04714372
Drug: FT538
Normalized name: Fidanacogene elaparvovec
DrugBank: Fidanacogene elaparvovec (DB16783)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FT538 is administered as an IV infusion via gravity using an IV administration set with an in-line filter at the patient's assigned dose levels (DL) on Day 1, Day 8, and Day 15
Study: NCT04714372
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine 25 mg/m\^2 is administered as a 1 hour intravenous (IV) infusion per institutional guidelines once a day on 2 consecutive days (Day -4, and Day -3).
Study: NCT00189761
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06098014
Drug: Thalidomide Capsules
Normalized name: Thalidomide Capsules
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: To see safety and efficacy of Thalidomide in Transfusion depended thalassemia
Study: NCT05041101
Drug: Eribulin Mesylate
Normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT05041101
Drug: Grapiprant
Normalized name: Grapiprant
DrugBank: Grapiprant (DB12836)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT00000851
Drug: Stavudine
Normalized name: Stavudine
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000851
Drug: Didanosine
Normalized name: Didanosine
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002103
Drug: Trimetrexate glucuronate
Normalized name: Trimetrexate Glucuronate
DrugBank: Trimetrexate (DB01157)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05966818
Drug: Dapagliflozin and Standard therapy (ACEI or ARB).
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dapagliflozin (Diglifloz) 10 mg orally once daily for 24 weeks and the standard therapy (ACEI or ARB).
Study: NCT06362408
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Older patients who have used dexmedetomidine(safe use range: 0.2\~1.0 μg/(kg·h)) for anesthesia induction or maintenance during surgery were classified as the DEX group. On the contrary, patients who did not use dexmedetomidine throughout the entire anesthesia process were identified as the Non-DEX group.
Study: NCT06203431
Drug: ET-26
Normalized name: Chloride/Dextrose/Potassium/Sodium 290 MG/1 PACKET-6 GM/1 PACKET-180 MG/1 PACKET-260 MG/1 PACKET Oral Powder for Solution
DrugBank: Potassium citrate (DB09125)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: freeze-dried powder injection，The initial dose is 0.8 mg/kg, with an additional 50% starting dose if needed. single dose, Infusion time was 60s ± 5s.
Study: NCT06203431
Drug: Etomidate Injectable Emulsion
Normalized name: etomidate Injection
DrugBank: Etomidate (DB00292)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: lipid emulsion ，The initial dose is 0.3 mg/kg, with an additional 50% starting dose if needed.single dose, Infusion time was 60s ± 5s.
Study: NCT06487949
Drug: valsartan-amlodipine 80/5 mg FDC
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: fix dose combination of valsartan 80 mg and Amlodipine 5 mg given as single pill
Study: NCT06487949
Drug: valsartan 80 mg and amlodipine 5 mg as free combination
Normalized name: valsartan and amlodipine
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Free combination of valsartan 80 mg and amlodipine 5 mg given separately
Study: NCT04722718
Drug: Sintilimab+Apatinib+Albumin-Bound Paclitaxel(Nab-Paclitaxel)+Carboplatin
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sintilimab:200mg,ivgtt,d1,21days/cycle;Apatinib:250mg po,d1-14days,21days/cycle;Albumin-Bound Paclitaxel(Nab-Paclitaxel):125mg/m2,ivgtt,d1,d8,21days/cycle;Carboplatin:AUC=1.5,ivgtt,d1,d8, 21days/cycle.Monitoring of blood routine, biochemical and urine routine, electrocardiogram, and record the patient's drug-related adverse reactions every cycle,according to the curative effect of patients, compliance and tolerance, neoadjuvant therapy 6 cycles,every 2 cycles to evaluate curative effect (ultrasonic, breast X-ray CT, bone scan, brain, lungs, assessment and breast MRI imaging).
Study: NCT00226642
Drug: Sertralin
Normalized name: Sertraline
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05434546
Drug: Sepranolone
Normalized name: Sepranolone
DrugBank: Sepranolone (DB12972)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with 10 mg Sepranolone s.c. twice weekly for 12 weeks alongside patient's standard of care Tourette treatment.
Study: NCT04960891
Drug: Tebentafusp
Normalized name: Tebentafusp
DrugBank: Tebentafusp (DB15283)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Concentrate solution for intravenous infusion
Study: NCT05742620
Drug: anlotinib+CAPEOX/SOX
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with colorectal cancer use the anlotinib+CAPEOX protocol, and patients with gastric cancer use the anlotinib+SOX protocol.~Anlotinib: 12mg, administered once a day on day 1-14, taken about half an hour before breakfast (the time of daily administration should be the same as much as possible), delivered with warm water, repeated once every three weeks;~CAPEOX: capecitabine 1000mg/m2 each time, oral, twice a day, 1-14 days; Oxaliplatin: 130mg/m2 iv drip d1.~SOX: Tegio: 100mg/day, continuous medication for 2 weeks, stop for 1 week; Oxaliplatin: 130mg/m2 iv drip d1.
Study: NCT04516681
Drug: Adebrelimab
Normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mg/Kg intravenously every 3 weeks
Study: NCT00000899
Drug: Nelfinavir mesylate
Normalized name: Nelfinavir Mesylate
DrugBank: Nelfinavir (DB00220)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000899
Drug: Lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00000899
Drug: Filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00000899
Drug: Stavudine
Normalized name: Stavudine
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00173667
Drug: Nifedipine 30 mg GITS
Normalized name: nifedipine 30 MG
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05615467
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered orally.
Study: NCT05615467
Drug: Iohexol
Normalized name: Iohexol
DrugBank: Iohexol (DB01362)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered IV.
Study: NCT05578404
Drug: Cholecalciferol
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vit D is a fat-soluble vitamin, provided by sunlight and activated by kidneys and liver.
Study: NCT01320410
Drug: ISM®
Normalized name: Isosmotic Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05558410
Drug: VX-548
Normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets for oral administration.
Study: NCT04779645
Drug: REMD-477
Normalized name: remdesivir
DrugBank: Remdesivir (DB14761)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 12-Week, once weekly subcutaneous injection with 70mg REMD-477
Study: NCT05139030
Drug: bupivacaine liposome injectable suspension
Normalized name: bupivacaine liposome Injection
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adductor canal block with EXPAREL
Study: NCT05139030
Drug: Bupivacaine Hydrochloride
Normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adductor Canal Block with bupivacaine HCl
Study: NCT05920213
Drug: Polyethylene Glycols
Normalized name: polyethylene glycols
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 280g/ 24 hours for 5 days
Study: NCT05920213
Drug: Lactulose oral solution
Normalized name: lactulose Oral Solution
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 60-120 ml per day for 5 days
Study: NCT05159193
Drug: trastuzumab (H)
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: trastuzumab (H) 8 mg/kg loading dose, 6 mg/kg maintenance doses, i.v., d1, q3w
Study: NCT05159193
Drug: pertuzumab (P)
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: pertuzumab (P) 840 mg loading dose, 420 mg maintenance doses, i.v., d1, q3w
Study: NCT05159193
Drug: docetaxel (T)
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: docetaxel (T) 90\~100 mg/m\^2, i.v., d1, q3w
Study: NCT05159193
Drug: docetaxel (T)
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: docetaxel (T) 75 mg/m\^2, i.v., d1, q3w
Study: NCT05159193
Drug: carboplatin (Cb)
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: carboplatin (Cb) AUC 6, i.v., d1, q3w
Study: NCT05809453
Drug: Cocaine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine will be administered intranasally prior to entering the warm environmental conditions and performing 60 minutes of exercise.
Study: NCT04558502
Drug: Amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotic for H. pylori eradication
Study: NCT05809453
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine will be administered intranasally prior to entering the warm environmental conditions and performing 60 minutes of exercise.
Study: NCT04558502
Drug: colloidal bismuth pectin
Normalized name: bismuth / pectin
DrugBank: Pectin (DB11158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastric mucosal protective drug with anti-H. pylori effect
Study: NCT04558502
Drug: esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Proton pump inhibitor
Study: NCT05641649
Drug: Sodium valproate and valproic acid extended release tablet
Normalized name: valproate Extended Release Oral Tablet
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Test or innovator tablet formulation of sodium valproate and valproic acid will be administered orally to the volunteers on each study days in fasting condition. Volunteers will be receiving a single tablet of either of the formulations on the study days by a randomization technique so that each of them receives both formulations during the study period.
Study: NCT01089192
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT05647993
Drug: Cefazolin
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All the participants will receive the cefazolin intravenously. The dosage of the cefazolin is depend on participant's weight. The participant with weight less than 80kg will receive cefazolin 1 gm and between 80-120kg will receive cefazolin 2 gm and for the participant with more than 120kg will receive cefazolin 3 gm before the incision.
Study: NCT05647993
Drug: Sodium Chloride 0.9% Intravenous Solution
Normalized name: Sodium Chloride 0.9% Intravenous Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For the placebo group will receive the cefazolin intravenously and 0.9% NaCl 100ml before the incision
Study: NCT04654507
Drug: Dexamethasone Oral
Normalized name: dexamethasone Oral Tablet
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Drug: Dexamethasone 0.3mg/kg/dose twice daily for 3 days
Study: NCT06107829
Drug: Valbenazine Oral Capsule
Normalized name: valbenazine Oral Capsule
DrugBank: Valbenazine (DB11915)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Open-label twenty-four-week treatment with valbenazine oral capsules (up to 80 mg/day) to test the safety and effectiveness of this medication in ameliorating the signs of tardive dyskinesia in persons with intellectual disability.
Study: NCT05856864
Drug: Cadonilimab Injection
Normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cadonilimab Injection, 10mg/kg, intravenous drip ,q2w,
Study: NCT05856864
Drug: Ramucirumab Injection
Normalized name: ramucirumab Injection
DrugBank: Ramucirumab (DB05578)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ramucirumab Injection，8mg/kg, intravenous drip ,q2w,
Study: NCT04691661
Drug: Radotinib HCl 50 mg
Normalized name: meclizine hydrochloride 50 MG
DrugBank: Radotinib (DB12323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enrolled subject will continue to administer Radotinib 50mg/day, 100mg/day, 150mg/day, 200mg/day, depending on the dose level once daily for 6 months.
Study: NCT06435507
Drug: IM-250 (50 mg)
Normalized name: triclabendazole 250 MG
DrugBank: Triclabendazole (DB12245)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose
Study: NCT06435507
Drug: IM-250 (100 mg)
Normalized name: triclabendazole 250 MG
DrugBank: Triclabendazole (DB12245)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose
Study: NCT06435507
Drug: IM-250 (200 mg)
Normalized name: triclabendazole 250 MG
DrugBank: Triclabendazole (DB12245)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose
Study: NCT06435507
Drug: IM-250 (400 mg)
Normalized name: triclabendazole 250 MG
DrugBank: Triclabendazole (DB12245)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose
Study: NCT03528681
Drug: Sodium Zirconium Cyclosilicate 5g
Normalized name: SODIUM ZIRCONIUM CYCLOSILICATE 5GM/PKT
DrugBank: Sodium zirconium cyclosilicate (DB14048)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Suspension administered Sodium Zirconium Cyclosilicate 5g orally once daily for 28 days after the open label initial phase with suspension administered Sodium Zirconium Cyclosilicate 10g orally three times per day for at most 2 days.
Study: NCT03528681
Drug: Sodium Zirconium Cyclosilicate 10g
Normalized name: SODIUM ZIRCONIUM CYCLOSILICATE 10GM/PKT
DrugBank: Sodium zirconium cyclosilicate (DB14048)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Suspension administered Sodium Zirconium Cyclosilicate 10g orally once daily for 28 days after the open label initial phase with suspension administered Sodium Zirconium Cyclosilicate 10g orally three times per day for at most 2 days.
Study: NCT04886765
Drug: ALMB-0168
Normalized name: ALMB-0168
DrugBank: ALMB-0168 (DB16926)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALMB-0168 will be administered intravenously until either the disease progresses or intolerable toxicity occurs.
Study: NCT01374282
Drug: Cuprimine (penicillamine)
Normalized name: penicillamine Oral Capsule [Cuprimine]
DrugBank: Penicillamine (DB00859)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosage determined by the physician based on indication for treatment
Study: NCT02762591
Drug: Pimavanserin tartrate
Normalized name: Pimavanserin tartrate
DrugBank: Pimavanserin (DB05316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pimavanserin tartrate 40 mg, tablet, taken as two 20 mg tablets, once daily by mouth
Study: NCT05645094
Drug: Envafolimab
Normalized name: Envafolimab
DrugBank: Envafolimab (DB15769)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive single drug therapy of Envafolimab (300mg) once every two weeks. Patients who do not have tumor regression after 3 months of treatment should be judged by the investigator whether to adopt standard chemoradiotherapy plus surgery. Patients with tumor regression should continue to receive Envafolimab therapy until 6 months. For patients who do not reach complete clinical response (cCR) after 6 months of treatment, the investigator shall determine whether to perform standard chemoradiotherapy or radical surgery. For patients who reach cCR, they could receive the observation waiting or local resection which depend on the investigator. Patients should be followed up until reaching cCR or 3 years after surgery.
Study: NCT05325164
Drug: Methadone
Normalized name: Methadone
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methadone
Study: NCT05325164
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine
Study: NCT06417684
Drug: Amitriptyline
Normalized name: Amitriptyline
DrugBank: Amitriptyline (DB00321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg prescribed to be taken once daily for 90 days each evening.
Study: NCT05200988
Drug: Ipilimumab + nivolumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Induction with immune checkpoint blockade: ipilimumab 3mg/kg on day 1, pilimumab 3mg/kg plus nivolumab 1mg/kg on day 22, and nivolumab 3mg/kg on day 43~Response evaluation after the last cycle of checkpoint inhibition.~Chemoradiation will start 10-12 weeks after start of checkpoint inhibition according to the following scheme:~* Mitoycine C (12mg/m2) on the first day of radiotherapy, followed by either 5-fluorouracil intravenously (500mg/m2) five days a week during week one and four of radiation, or oral capecitabin (2x825mg/m2) every day during the radiation period~* Radiation with a preference for a four-week schedule, in which 55 Gy will be administered using intensity modulated radiation therapy
Study: NCT06057571
Drug: TT-00420 (tinengotinib)
Normalized name: TT 173
DrugBank: TT 173 (DB17717)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TT-00420 (tinengotinib) tablet will be administered orally once daily per protocol defined schedule.
Study: NCT04887298
Drug: Liposomal Annamycin (L-Annamycin)
Normalized name: Ansamycin
DrugBank: Annamycin (DB06420)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-hour intravenous (IV) infusion of L-Annamycin on Day 1 followed by 20 days off of study drug (i.e., 1 treatment cycle= 21 days)
Study: NCT00071708
Drug: Duloxetine Hydrochloride
Normalized name: Duloxetine Hydrochloride
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06598943
Drug: Eltrekibart
Normalized name: Eltrekibart
DrugBank: Eltrekibart (DB19017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered
Study: NCT06598943
Drug: Mirikizumab
Normalized name: Mirikizumab
DrugBank: Mirikizumab (DB14910)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered
Study: NCT04243824
Drug: Gallium 68 Macro-aggregated albumin
Normalized name: Albumin Aggregated
DrugBank: Gallium nitrate (DB05260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The radiotracer, Ga-68 MAA, will be administered prior to PET/MRI scan.
Study: NCT06380881
Drug: SHR-2017
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-2017
Study: NCT05809687
Drug: DKP21102_C
Normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo
Study: NCT04996719
Drug: Rapamune
Normalized name: Rapamune
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: We will start the dose at 0.5mg capsule every other day for 2 weeks. If participants tolerate this dose and trough blood levels are (≤4ng/mL), the dose of rapamycin will be increased to 0.5mg daily for the duration of the study. If necessary, dose can remain at 0.5 mg every other day, depending on the trough level. To avoid immunosuppression, we will target lower dose of rapamycin, maintain lower trough serum levels (≤4ng/mL).
Study: NCT04711837
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol for induction of general anesthesia.
Study: NCT05257122
Drug: Fruquintinib
Normalized name: fruquintinib
DrugBank: Fruquintinib (DB11679)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fruquintinib 5mg qd, d1-21, q28d
Study: NCT04937699
Drug: Standard-DAPT of Ticagrelor plus aspirin
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor 90mg bid+Aspirin 100mg qd for 1 month after PCI, Randomized subjects continue for another 11 months
Study: NCT04937699
Drug: Sequential monotherapy of Ticagrelor and clopidogrel
Normalized name: Ticagrelor
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ticagrelor 90mg bid+Aspirin 100mg qd for 1 month after PCI, Randomized subjects switch to ticagrelor 90mg bid for 5 months; then clopidogrel 75mg qd, for another 6 months.
Study: NCT05669521
Drug: TK-112690
Normalized name: TK-112690
DrugBank: TK-112690 (DB18822)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TK112690 treatment Post 5-FU chemotherapy